Education
About Us
Working with TipRanks
Follow Us
Noile-Immune Biotech Inc. (JP:4893)
:4893
Top Page
Noile-Immune Biotech Inc.
(4893)
Select Model
Select Model
Rating:43Neutral
Price Target:
¥126.00
▼(-5.97% Downside)
The score is primarily held down by weak financial performance (worsening losses and accelerating cash burn) and bearish technicals (price below all key moving averages with negative MACD). Valuation is only neutral because the negative P/E is not informative for a loss-making company and there is no dividend yield data.
Positive Factors
Conservative Balance Sheet
A zero-debt balance sheet reduces solvency risk and financial fragility, providing stability in uncertain market conditions.
High Gross Profit Margins
High gross margins indicate strong unit economics, which can support profitability once the company scales and controls expenses.
Proprietary Cell Engineering Technologies
Proprietary technologies can provide a competitive edge in the biotech industry, fostering innovation and potential market leadership.
Negative Factors
Worsening Cash Burn
Accelerating cash burn increases financing risk and may necessitate external capital, impacting long-term financial sustainability.
Declining Revenue
Declining revenue suggests limited commercial traction, which can hinder growth prospects and investor confidence in the long term.
Large Operating Losses
Persistent large losses indicate an unsustainable expense base, requiring significant operational improvements to achieve profitability.
Noile-Immune Biotech Inc. (4893) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥6.32B
Dividend YieldN/A
Average Volume (3M)85.17K
Price to Earnings (P/E)―
Beta (1Y)1.36
Revenue Growth-12.01%
EPS Growth26.66%
CountryJP
Employees25
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.46
Shares Outstanding43,276,764
10 Day Avg. Volume110,290
30 Day Avg. Volume85,173
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)1.56
Price to Sales (P/S)970.16
P/FCF Ratio-8.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Noile-Immune Biotech Inc. Business Overview & Revenue Model
Company DescriptionNoile-Immune Biotech Inc. researches and develops CAR-T cells for cancer immunotherapies. The company was incorporated in 2015 and is headquartered in Minato, Japan.
How the Company Makes MoneyNoile-Immune Biotech Inc. generates revenue through the development and commercialization of its proprietary immunotherapy products. The company's primary revenue streams include licensing agreements, partnerships with pharmaceutical companies, and milestone payments related to the progress of its drug candidates through clinical trials. Additionally, Noile-Immune Biotech may receive royalties from the commercialization of its licensed technologies and products. Strategic collaborations with other biotech firms and research institutions also play a significant role in advancing its research and development efforts, potentially leading to additional revenue opportunities.
Noile-Immune Biotech Inc. Financial Statement Overview
Summary
Noile-Immune Biotech faces significant challenges with consistent net losses and negative cash flows, despite having a strong balance sheet with no debt and high equity. The company needs to improve its operational efficiency and revenue generation to attain profitability and sustainable cash flow.Income Statement
The company shows significant volatility in revenue, with total revenue sharply decreasing from 2020 to 2023, followed by a substantial rise in 2024. Gross profit margins are consistently high, but the net profit margin remains negative due to significant net losses. EBIT margins are also negative, indicating operational challenges.Balance Sheet
Noile-Immune Biotech maintains a strong equity position with no debt, resulting in a debt-to-equity ratio of zero. The equity ratio is high, reflecting financial stability. However, the company has been incurring substantial losses, which may affect future equity levels.Cash Flow
The company exhibits negative free cash flow, indicating cash outflows exceeding inflows from operations. However, the high cash reserves suggest a buffer against operational cash shortfalls, although reliance on financing inflows could pose future risks.| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.14M | 7.59M | 316.82M | 625.78M | 100.73M | 97.28M |
| Gross Profit | 9.14M | 7.39M | 314.56M | 618.71M | 77.83M | 94.31M |
| EBITDA | -519.02M | -1.07B | -775.39M | -106.34M | -767.51M | -591.67M |
| Net Income | -692.16M | -964.46M | -1.13B | -386.62M | -795.03M | -636.65M |
Balance Sheet | ||||||
| Total Assets | 4.38B | 4.80B | 5.78B | 4.64B | 4.27B | 2.67B |
| Cash, Cash Equivalents and Short-Term Investments | 4.31B | 4.67B | 5.56B | 4.52B | 4.14B | 2.55B |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 68.07M | 74.67M | 91.49M | 340.42M | 85.72M | 75.88M |
| Stockholders Equity | 4.31B | 4.73B | 5.69B | 4.30B | 4.19B | 2.60B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -887.81M | -873.08M | -107.18M | -777.14M | -300.64M |
| Operating Cash Flow | 0.00 | -887.81M | -873.08M | -107.18M | -777.14M | -300.64M |
| Investing Cash Flow | 0.00 | 557.00K | -5.32M | 0.00 | -4.03M | 0.00 |
| Financing Cash Flow | 0.00 | 2.50M | 1.91B | 487.62M | 2.37B | 996.35M |
Noile-Immune Biotech Inc. Technical Analysis
Neutral
134.00
Price Trends
148.26
Negative
163.05
Negative
162.71
Negative
Market Momentum
-2.34
Negative
49.28
Neutral
65.28
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4893, the sentiment is Neutral. The current price of 134 is below the 20-day moving average (MA) of 137.75, below the 50-day MA of 148.26, and below the 200-day MA of 162.71, indicating a neutral trend. The MACD of -2.34 indicates Negative momentum. The RSI at 49.28 is Neutral, neither overbought nor oversold. The STOCH value of 65.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4893.
Noile-Immune Biotech Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ¥44.44B | -18.98 | ― | ― | -9.04% | 13.09% | |
45 Neutral | ¥7.69B | -4.19 | ― | ― | -93.79% | -1332.86% | |
44 Neutral | ¥5.48B | -2.29 | ― | ― | ― | 25.25% | |
43 Neutral | ¥6.32B | -7.86 | ― | ― | -12.01% | 26.66% | |
42 Neutral | ¥2.96B | -2.96 | ― | ― | -9.77% | -13.86% | |
42 Neutral | ¥8.92B | -7.99 | -63.25% | ― | 99.87% | 40.60% |
* Healthcare Sector Average
JP:4893
Noile-Immune Biotech Inc.
142.00
-42.00
-22.83%
JP:4564
OncoTherapy Science
23.00
0.00
0.00%
JP:3750
Cytori Cell Research Institute, Inc.
862.00
-23.00
-2.60%
JP:4588
Oncolys BioPharma, Inc.
1,561.00
1,048.00
204.29%
JP:4598
Delta-Fly Pharma, Inc.
371.00
-157.00
-29.73%
JP:4884
Kringle Pharma, Inc.
397.00
-824.00
-67.49%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.